Amgen Inc. (AMGN) Market Performance Summary for February 11, 2026
Stock Performance Overview
On February 11, 2026, Amgen Inc. (NASDAQ: AMGN) experienced a modest increase in its stock price. The stock opened at $365.14 and closed at $366.58, reflecting a change of $1.93, or 0.53%. The stock reached a high of $368.51 and a low of $361.00 during the trading session. The total trading volume for the day was approximately 2.77 million shares, contributing to a total market capitalization of approximately $197.59 billion.
Intraday Price Movements
The stock's performance throughout the day showed fluctuations typical of a volatile market environment. The opening price of $365.14 indicated a slight increase from the previous day's close of $364.65. As trading progressed, AMGN's stock price peaked at $368.51 before settling lower towards the end of the session. The price change of $1.93 represented a 0.53% increase, which is a relatively stable performance in the context of the broader market.
Recent Financial Results
Amgen recently reported its financial results for the fourth quarter and full year of 2025 on February 3, 2026. The results were noteworthy, with the company announcing earnings per share (EPS) of $5.29, which exceeded analysts' expectations of $4.76. This EPS figure, however, represented a slight decrease from the $5.31 reported in Q4 2024.
The revenue for the quarter was $9.87 billion, surpassing the consensus estimate by 4.23% and showing an increase from $9.09 billion in the same quarter of the previous year.
For the full year 2025, Amgen provided a revenue estimate of $36.92 billion and a current consensus EPS estimate of $21.85. The guidance for the first quarter of 2026 included a revenue estimate of $8.33 billion and an EPS estimate of $4.86. These results and projections indicate a solid financial performance and growth trajectory for the company.
Analyst Insights and Market Context
Analysts have generally maintained a positive outlook on Amgen's stock following the recent earnings report. The Zacks Rank for Amgen is currently #3 (Hold), suggesting that the stock is expected to perform in line with the market.
Notably, Daiwa Securities recently raised its price target for Amgen to $410 from $370, maintaining an "outperform" rating, which signals a potential upside of approximately 10% from the current price levels.
The stock's performance since the beginning of the year has been impressive, with an increase of about 5.3%, compared to a 1.9% gain for the S&P 500 index. This relative strength may be attributed to Amgen's strong product pipeline and robust financial health, which continue to attract both institutional and retail investors.
Conclusion
In summary, Amgen Inc.'s stock showed a stable performance on February 11, 2026, with a modest increase in price following a robust earnings report. The company's strong financial results, coupled with positive analyst sentiment, provide a favorable outlook for investors. The stock's intraday movements were reflective of broader market trends, and the overall market capitalization remains strong, positioning Amgen as a significant player in the biotechnology sector.
Explore more exclusive insights at nextfin.ai.
